United States v. Thomas Malone, Jr.

828 F.3d 331
CourtCourt of Appeals for the Fifth Circuit
DecidedJuly 6, 2016
Docket14-31426 Cons w/ 15-30011
StatusPublished
Cited by123 cases

This text of 828 F.3d 331 (United States v. Thomas Malone, Jr.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Thomas Malone, Jr., 828 F.3d 331 (5th Cir. 2016).

Opinion

*334 PATRICK E. HIGGINBOTHAM, Circuit Judge:

IT IS ORDERED that the petitions for panel rehearing and the petitions for rehearing en banc are DENIED.' We WITHDRAW Part II.B of the opinion previously-filed on December 11, 2015, and SUBSTITUTE the following amended opinion.

Thomas William Malone, Jr. and Drew T. Green pleaded guilty to one count of conspiracy to distribute and possess with the intent to distribute AM-2201, a controlled substance analogue, in violation of 21 U.S.C. §§ 846, 841(b)(1)(c), 813, 802(32)(A). The district court sentenced them both to 117 months of imprisonment followed by three years of supervised release. They appeal their sentences on several different grounds. We AFFIRM.

I.

Thomas William Malone, Jr. and Drew T. Green were the owners of NutraGenom-ics Mfg L.L.C. Prior to March 2011, Nu-traGenomics distributed JWH-018 throughout the United States. When new federal and state laws banned this substance, NutraGenomics discontinued its distribution and began selling several new synthetic cannabinoids, one of which was AM-2201. Malone and Green sold AM-2201 both in bulk and as part of a product called “Mr. Miyagi” — a mixture of AM-2201 and vegetable material that visually resembled marijuana. Though Mr. Miyagi was, with a wink, labeled as potpourri not fit for human consumption, the expectation was that the user would smoke the product in order to get high off its active ingredient, AM-2201. Malone and Green brought in Boyd A. Barrow and Joshua Espinoza to manufacture and distribute Mr. Miyagi, both now co-defendants. They in turn sold a large quantity of Mr. Miyagi to Richard Buswell, who distributed it at stores' throughout Louisiana.

On September 4, 2012, a federal grand jury in the Western District of Louisiana returned a superseding indictment charging Malone, Green, and several co-defendants with one count of conspiracy to distribute and possess with the intent to distribute AM-2201, a controlled substance analogue, one count of conspiracy to introduce and cause to be introduced misbranded drugs into interstate commerce, and one count of conspiracy to commit money laundering. Within about two weeks, Malone and Green had reached plea agreements with the Government in which they agreed to cooperate and plead guilty to the count of conspiracy to distribute AM-2201 in exchange for the dismissal of the remaining counts. They pled guilty to one count of conspiracy to distribute and possess with the intent to distribute a Schedule I Controlled Dangerous Substance, in violation of 21 U.S.C. §§ 846, 841(b)(1)(c), 813, 802(32)(A). As part of their pleas, Malone and Green admitted to distributing not less than 1400 kilograms of AM-2201, and earning not less than $10,000,000 from the conspiracy.

The guilty pleas were accepted, and the probation office prepared presentence reports (“PSRs”). Because AM-2201 is not listed in either the Drug Quantity Table or the Drug Equivalency Tables, the PSRs had to “determine the base offense level using the marihuana equivalency of the most closely related controlled substance” to AM-2201. 1 The Sentencing Guidelines require that three factors guide this inquiry:

(A) Whether the controlled substance not referenced in this guideline has a chemical structure that is substantially *335 similar to a controlled substance referenced in this guideline.
(B) Whether the controlled substance not referenced in this guideline has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance referenced in this guideline.
(C) Whether a lesser or greater quantity of the controlled substance not referenced in this guideline is needed to produce a substantially similar effect on the central nervous system as a controlled substance referenced in this guideline. 2

Based upon the consideration of these factors, the PSRs determined that Tetrahy-drocannabinol, or THC, was the “most closely related controlled substance” to AM-2201. The Drug Equivalency Tables specify a 1 to 167 ratio for converting THC into marijuana; that is, the Sentencing Guidelines treat one gram of THC as equivalent to 167 grams of marijuana. 3 Using this ratio, the PSRs concluded that Appellants should be held responsible for 233,800 kilograms of marijuana 4 — and that the base offense level for both should be set at 38, the highest level set forth by the Drug Quantity Table. 5

Appellants objected to the use of a 1:167 ratio to convert the 1400 kilograms of AM-2201 into marijuana. Instead, they argued that a 1:1 ratio was appropriate because marijuana, not THC, is the “most closely related controlled substance” to AM-2201. Alternatively, they asked the district court to exercise its discretion under Kimbrough v. United States 6 to reject the 1:167 ratio. These objections prompted an evidentiary hearing. Two experts — one for the Government and one for the defense — testified at length in the hearing about the available scientific data on AM-2201. The Government’s expert, Dr. Jordan Trecki, relied on five different categories of evidence to support his opinion that THC is the “most closely related substance” to AM-2201: (1) a “binding study” showing that THC and AM-2201 bind to the same cannabinoid receptor; (2) a “functional assay” showing that THC and AM-2201 both activate this receptor; (3) a drug discrimination study showing that (a) rats cannot tell the difference between THC and AM-2201 and that (b) AM-2201 is more potent than THC; (4) a “tetrad study” showing that rats react similarly to THC and JWH-018, an analogue of AM-2201; and (5) case studies showing that THC and AM-2201 have similar effects on human users. The defense expert, Dr. Nicholas Cozzi, devoted much of his testimony to criticizing the evidence relied upon by Dr. Trecki. In particular, Dr. Cozzi criticized Dr. Trecki for relying on animal studies — as opposed to human studies — and combining the results of several different studies — each of which was inconclusive standing alone — to form his opinion. When asked to provide his opinion, Dr. Cozzi remarked that it was “kind of a nonscience question,” but testified that marijuana was the “most closely related controlled substance” to AM-2201 because “it’s consumed in the same way and it’s consumed for the same effect.” Both ex *336 perts agreed, however, that there was no scientific basis for the 1:167 ratio used to convert THC into marijuana. 7

The next day, the district court issued an oral ruling on Appellants’ objections. Citing the evidence relied upon by Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Oliver
Fifth Circuit, 2024
United States v. Seneca
Fifth Circuit, 2023
United States v. Weeks
Fifth Circuit, 2023
United States v. Chavarria
Fifth Circuit, 2023
United States v. Thompson
Fifth Circuit, 2023
United States v. Drayton
Fifth Circuit, 2023
United States v. Cimino
Fifth Circuit, 2022
United States v. Smith
Fifth Circuit, 2022
United States v. Rivera
Fifth Circuit, 2021
United States v. Miller
Fifth Circuit, 2021
United States v. Meza
Fifth Circuit, 2021
United States v. Tyvon Taylor
973 F.3d 414 (Fifth Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
828 F.3d 331, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-thomas-malone-jr-ca5-2016.